



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 147333

TO: Deborah Lambkin
Location: REM-5C18
Art Unit: 1626
Wednesday, March 16, 2005

Case Serial Number: 10/758791

From: Mary Hale
Location: Biotech/Chem Library
Rem 1D86
Phone: 2-2507

Mary.Hale@uspto.gov

Search Notes

Feel free to contact me if you have any questions.

147333

Access DB#

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Deborah Lambkin (STIC) Examiner #: 71300 Date: 3/9/05
 Art Unit: 1626 Phone Number 302-0648 Serial Number: 10/758,791
 Mail Box and Bldg/Room Location: REM 5809 Results Format Preferred (circle): PAPER DISK E-MAIL


If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Heterocyclic side chain containing -N-sub. unstable inh.
 Inventors (please provide full names): Stanislav P. Khand et al

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



Cl. 1 attached.

STAFF USE ONLY

Searcher: _____ Type of Search _____ Vendors and cost where applicable _____
 Searcher Phone #: _____ NA Sequence (#) _____ STN _____
 Searcher Location: _____ AA Sequence (#) _____ Dialog _____
 Date Searcher Picked Up: _____ Structure (#) _____ Questel/Orbit _____
 Date Completed: _____ Bibliographic _____ Dr. Link _____
 Searcher Prep & Review Time: _____ Litigation _____ Lexis/Nexis _____
 Clerical Prep Time: _____ Fulltext _____ Sequence Systems _____
 Online Time: _____ Patent Family _____ WWW/Internet _____
 Other _____ Other (specify) _____

10 | 758791

21 ANSWERS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.35	168.40

FILE 'HCAPLUS' ENTERED AT 13:32:56 ON 16 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

Searched by: Mary Hale 571-272-2507 REM 1D86

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Mar 2005 VOL 142 ISS 12
FILE LAST UPDATED: 15 Mar 2005 (20050315/ED)


This file contains CAS Registry Numbers for easy and accurate substance identification.

L4 6 L3

=> d 1-6 cbib abs hitstr

L4 ANSWER 1 OF 6 HCAPLAUS COPYRIGHT 2005 ACS on STN
 2003:717760 Document No. 139:245903 Preparation of
 ((hetero)arylsulfonylamino)-[1-substituted-piperidin-4-yl]-acetic acids
 as metalloprotease inhibitors. Pikul, Stanislaw; Ohler, Norman Eugene;
 Almstead, Neil Gregory; Laughlin, Steven Karl; Natchus, Michael George;
 De, Bivannath (USA). U.S. Pat. Appl. Publ. US 2003/171400 A1 20030911, 33
 pp., Cont.-in-part of Appl. PCT/US01/08783. (English). CODEN: USXXCO.
 APPLICATION: US 2002-246201 20020918. PRIORITY: US 2000-PV191303
 20000321; WO 2001-US8783 20010320.

GI




II

AB The title compds. [I; R1 = OH, NHOH; R2 = H, alkyl, haloalkyl, etc.; A = (un)substituted monocyclic heterocycloalkyl; A can be connected to R2 to form (un)substituted monocyclic heterocycloalkyl; n = 0-4; E = a bond, alkyl, CO, etc.; X = H, alkyl, aryl, etc.; G = S, O, N; N, etc.; Z = cycloalkyl, heterocycloalkyl, etc.] such as II which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes such as arthritis and cancer, were claimed and formulated (preps. are given but no data are given for intermediates and final compds.).


IT 597582-84-8P, 2-[[[4'-Bromobiphenyl-4-yl]sulfonyl]amino]-N-hydroxy-2-[1-[(morpholin-4-yl)carbonyl]piperidin-4-yl]acetamide
 597582-85-9P, N-Hydroxy-2-[[[4'-methoxybiphenyl-4-yl]sulfonyl]amino]-2-[1-phenethylpiperidin-4-yl]acetamide
 597582-86-0P, N-Hydroxy-2-[[[4'-methoxybiphenyl-4-yl]sulfonyl]amino]-2-[1-(thiazol-2-yl)methyl]piperidin-4-yl]acetamide
 597582-87-1P, N-Hydroxy-2-[[[4'-methoxybiphenyl-4-yl]sulfonyl]amino]-2-[1-(2-phenoxyacetyl)piperidin-4-yl]acetamide
 597582-88-2P, N-Hydroxy-2-[1-(2-methoxyacetyl)piperidin-4-yl]-2-[[[4'-methoxybiphenyl-4-yl]sulfonyl]amino]acetamide 597582-89-3P, N-Hydroxy-2-[[[4'-methoxybiphenyl-4-yl]sulfonyl]amino]-2-[1-(phenylmethylsulfonyl)piperidin-4-yl]acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of
 [(hetero)arylsulfonylamino]-[1-substituted-


L4 ANSWER 1 OF 6 HCAPLAUS COPYRIGHT 2005 ACS on STN (Continued)
 piperidin-4-yl]-acetic acids as metalloprotease inhibitors)
 RN 597582-84-8 HCAPLAUS
 CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-bromo[1,1'-biphenyl]-4-yl]sulfonyl]amino]-N-hydroxy-1-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 597582-85-9 HCAPLAUS
 CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 597582-86-0 HCAPLAUS
 CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]-1-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 597582-87-1 HCAPLAUS
 CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]-1-(phenoxyacetyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 HCAPLAUS COPYRIGHT 2005 ACS on STN (Continued)



RN 597582-88-2 HCAPLAUS
 CN 4-Piperidineacetamide, N-hydroxy-1-(methoxyacetyl)-α-[[[4'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 597582-89-3 HCAPLAUS
 CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]-1-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




IT 363525-92-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of
 [(hetero)arylsulfonylamino]-[1-substituted-piperidin-4-yl]-
 acetic acids as metalloprotease inhibitors)

RN 363525-92-6 HCAPLAUS
 CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]-1-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 HCAPLAUS COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 2 OF 6 HCAPIUS COPYRIGHT 2005 ACS ON STN
2003:570642 Document No. 139:117342 Preparation of
biphenylsulfonamidoheterocyclylcarboxylates as metalloprotease
inhibitors.

Pikul, Stanislaw; Ohler, Norman Eugene; Almstead, Neil Gregory; Laughlin,
Steven Karl; Matchus, Michael George; De, Biswanath; Hershberger, Paul
Mitchell (The Procter & Gamble Company, USA), U.S. Pat. Appl. Publ. US
2003139414 A1 20030724, 30 pp., Cont.-in-part of Appl. No.
PCT/US01/08931.


(English). CODEN: USXXCO. APPLICATION: US 2002-243511 20020913.
PRIORITY: US 2000-PV191302 20000321; WO 2001-US8931 20010302.

GI




AB Title compds. [I; R1 = OH, NHOH; R2 = H, alkyl, alkenyl, alkynyl,
heteroalkyl, haloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, aralkyl,
heteroaralkyl; R3 = alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl,
(hetero)cycloalkyl, aralkyl, heteroaralkyl; A = (substituted)
monocyclic
heterocycloalkyl having 3-8 ring atoms of which 1-3 are heteroatoms; a, n
= 0-4; E = bond, alkyl, CO, CO2, CONR4, SO2, CSNR4; R4 = H, alkyl,
alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl,
aryl, arylalkyl, heteroaryl, heteroaralkyl; X = H, alkyl, alkenyl,
alkynyl, heteroalkyl, haloalkyl, aryl, aralkyl, heteroaryl,
heteroaralkyl,
(hetero)cycloalkyl; G = S, O, NR5, CR5:CR5', N:CR5, N:N; R5, R5' = H,
alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl,
(hetero)cycloalkyl; G1 = S, O, NR6, CR6:CR6', N:CR6, N:N; R6, R6' = H,
alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl,
heterocycloalkyl; M = CH, N; Z = (CR7R7')aLR8; R7, R7' = H, alkyl,
alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, (hetero)cycloalkyl,
halo,
haloalkyl, OH, alkoxy; L = bond, O, SO2, CO, CONR9, NR9, NR9CO; b = 0-2;
R9 = H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalkyl,
heteroaralkyl, (hetero)cycloalkyl, haloalkyl; AR2, XR4, R7R9, R8R9 = atoms
to form a (substituted) heterocyclic ring containing 5-8 atoms of which 1-3
are heteroatoms; R8 = H, alkyl, alkenyl, alkynyl, halo, heteroalkyl,
haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, are claimed.
No synthetic or biol. data is given.
IT 362524-37-6P 564486-57-3P 564486-58-4P
564486-59-5P 564486-60-8P 564486-61-9P
564486-62-0P 564486-63-1P 564486-64-2P
564486-65-3P 564486-66-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


L4 ANSWER 2 OF 6 HCAPIUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 564486-60-8 HCAPIUS
CN 1-Piperidinecarboxylic acid, 4-[2-(hydroxyamino)-1-[[4'-methoxy(1,1'-
biphenyl)-4-yl)sulfonyl)methylamino]-2-oxoethyl]-, 2-methoxyethyl ester
(9CI) (CA INDEX NAME)




RN 564486-61-9 HCAPIUS
CN 1-Piperidinecarboxylic acid, 4-[1-[ethyl[[4'-methoxy(1,1'-biphenyl)-4-
yl)sulfonyl]amino]-2-(hydroxyamino)-2-oxoethyl]-, 2-methoxyethyl ester
(9CI) (CA INDEX NAME)




RN 564486-62-0 HCAPIUS
CN 1-Piperidinecarboxylic acid, 4-[2-(hydroxyamino)-1-[[4'-methoxy(1,1'-
biphenyl)-4-yl)sulfonyl]methylamino]-2-oxoethyl]-, 2-methoxyethyl
ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 HCAPIUS COPYRIGHT 2005 ACS ON STN (Continued)
(prepn. of biphenylsulfonamidoheterocyclylcarboxylates as
metalloprotease inhibitors)


RN 362524-37-6 HCAPIUS
CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy(1,1'-biphenyl)-4-
yl)sulfonyl)methylamino]-1-(4-morpholinylcarbonyl)- (9CI) (CA INDEX
NAME)



RN 564486-57-3 HCAPIUS
CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy(1,1'-biphenyl)-4-
yl)sulfonyl)methylamino]-1-(4-morpholinylcarbonyl)- (9CI) (CA
INDEX NAME)




RN 564486-58-4 HCAPIUS
CN 4-Piperidineacetamide, α-[ethyl[[4'-methoxy(1,1'-biphenyl)-4-
yl)sulfonyl]amino]-N-hydroxy-1-(4-morpholinylcarbonyl)- (9CI) (CA INDEX
NAME)




RN 564486-59-5 HCAPIUS
CN 4-Piperidineacetamide, α-[[[4'-fluoro(1,1'-biphenyl)-4-
yl)sulfonyl)methylamino]-N-hydroxy-1-(4-morpholinylcarbonyl)- (9CI) (CA
INDEX NAME)


L4 ANSWER 2 OF 6 HCAPIUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 564486-63-1 HCAPIUS
CN 1-Piperidinecarboxylic acid, 4-[2-(hydroxyamino)-1-[[4'-methoxy(1,1'-
biphenyl)-4-yl)sulfonyl]methylamino]-2-oxoethyl]-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)




RN 564486-64-2 HCAPIUS
CN 1-Piperidinecarboxylic acid, 4-[1-[[4'-fluoro(1,1'-biphenyl)-4-
yl)sulfonyl]methylamino]-2-(hydroxyamino)-2-oxoethyl]-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)



RN 564486-65-3 HCAPIUS
CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy(1,1'-biphenyl)-4-
yl)sulfonyl]methylamino]-1-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX
NAME)




RN 564486-66-4 HCAPIJUS
CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]methylamino]-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 HCAPIJUS COPYRIGHT 2005 ACS on STN (Continued)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. as selective matrix-degrading metalloproteinase (MMP-13) inhibitors useful as antiinflammatories)
RN 458560-22-0 HCAPIJUS
CN 1-Piperidinecarboxylic acid, 4-[[[1R]-1-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-2-(hydroxyamino)-2-oxoethyl]-, 2-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 458560-25-3 HCAPIJUS
CN 1-Piperidinecarboxylic acid, 4-[[[1R]-1-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-2-(hydroxyamino)-2-oxoethyl]-, 2-(1-naphthalenyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



2002:716273 Document No. 137:232912 Preparation of azacycloalkyl- and arylsulfonylamino-substituted acetic acid derivatives as selective matrix-degrading metalloproteinase (MMP-13) inhibitors useful as antiinflammatories. Fujimoto, Roger Aki; McQuire, Leslie Wighton; Monovich, Lauren G.; Nantemmet, Philippe; Parker, David Thomas; Robinson, Leslie Ann; Skiles, Jerry W.; Tommasi, Ruben Alberto (Novartis A.-G. Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.). PCT Int. Appl. WO 2002072577 A2 20020919. 76 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, (English). CODEN: PIXXD2. APPLICATION: WO 2002-EP2808 20020313. PRIORITY: US 2001-PV275819 20010314; US 2001-PV278572 20010322.

GI



AB Comps. I (e.g. (αR)-1-BOC-α-[[[5-(4-trifluoromethylphenyl)-2-thienyl)sulfonyl]amino]-4-piperidineacetic acid) wherein R represents OH or NHOH; R1 represents H, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid of from a sulfonic acid; R2 represents biarylsulfonyl or aryloxyarylsulfonyl; R3 represents H, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or

from a carbamic acid; R4 and R5 represent independently H, lower alkyl, lower alkoxy, carbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is 0-3; pharmaceutically acceptable prodrug derivs. thereof; pharmaceutically acceptable salts thereof; pharmaceutical compns. comprising said compds.; and their use for selectively inhibiting the matrix degrading metalloproteinase MMP-13 and preventing or treating matrix metalloproteinase dependent conditions in mammals. Typically, compds. of the invention inhibit collagenase-3 (MMP-13) with IC50s in the range of .apprx.0.1-100 nM and are substantially free of collagenase-1 (MMP-1) inhibition at effective MMP-13 inhibiting concns. The ratio of the IC50 for MMP-1 inhibition to the IC50 for MMP-13 inhibition is typically in the

range of .apprx.100-10,000. Although the methods of preparation are not claimed, 13 example preps. are included and >100 specific compds. with mass spectral data are included.

IT 458560-22-0P, (αR)-1-[[[2-Phenylethoxy]carbonyl]-α-[[[4-(4-chlorophenyl)phenyl)sulfonyl]amino]-4-piperidine-N-hydroxyacetamide 458560-25-3P, (αR)-1-[[[2-(1-Naphthyl)ethoxy]carbonyl]-α-[[[4-(4-chlorophenyl)phenyl)sulfonyl]amino]-4-piperidine-N-hydroxyacetamide

2001:713311 Document No. 135:272814
[(Biphenylsulfonyl)amino]-[1-substituted-piperidin-4-yl]-acetic acids as metalloprotease inhibitors. Pikul, Stanislaw; Ohler, Norman Eugene; Almstead, Neil Gregory; Laughlin, Steven Karl; Natchus, Michael George; De, Biswanath (Procter + Gamble Company, USA). PCT Int. Appl. WO 2001070691 A1 20010927. 56 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FI, GB, GD, GE, GH, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US8931 20010302. PRIORITY: US 2000-PV191302 20000321.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. [I; R1 = OH, NHOH; R2 = H, alkyl, alkenyl, etc.; R3 = alkyl, alkenyl, haloalkyl, etc.; A = (un)substituted monocyclic heterocycloalkyl; or A is bonded to R2 to form (un)substituted monocyclic heterocycloalkyl; n = 0-4; E = a bond, alkylene, CO, etc.; X = H, alkyl, aryl, etc.; G = S, O, N:N, etc.; G1 = S, O, N:N, etc.; M = CH, N; Z =

OMe, halo, etc.] such as compound II which are inhibitors of metalloproteases and


which are effective in treating conditions characterized by excess activity of these enzymes such as arthritis and cancer, were prepared and formulated (no data for intermediates and final compds.). Also described are pharmaceutical compns. comprising these compds., and methods of treating metalloprotease-related maladies using the compds. I or the pharmaceutical compns.

IT 362524-37-6P
RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
[(Biphenylsulfonyl)amino]-[1-substituted-piperidin-4-yl]-acetic acids as metalloprotease inhibitors


RN 362524-37-6 HCAPIJUS
CN 4-Piperidineacetamide, N-hydroxy-α-[[[4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]methylamino]-1-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 6 HCAPIJUS COPYRIGHT 2005 ACS on STN
 2001:713310 Document No. 135:257165 [(Hetero)arylsulfonylamino]-[1-substituted-piperidin-4-yl]-acetic acids as metalloprotease inhibitors. Pikul, Stanislaw; Ohler, Norman Eugene; Almstead, Neil Gregory; Laughlin, Steven Karl; Natchus, Michael George; De, Biswanath (Procter + Gamble Company, USA). PCT Int. Appl. WO 2001070690 A1 20010927, 69 pp.
 DESIGNATED STATES: W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FR, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CT, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LJ, MC, ML, MR, ME, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US8783 20010320. PRIORITY: US 2000-PV191303 20000321.
 GI



AB The title compds. [I; R1 = OH, NHOH; R2 = H, alkyl, haloalkyl, etc.; A = (un)substituted monocyclic heterocycloalkyl; A can be connected to R2 to form (un)substituted monocyclic heterocycloalkyl; n = 0-4; E = a bond, alkyl, CO, etc.; X = H, alkyl, aryl, etc.; G = S, O, N:N, etc.; Z = cycloalkyl, heterocycloalkyl, etc.] such as II which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes such as arthritis and cancer, were claimed and formulated (preps. were given but no data for intermediates and final compds.).
 IT 362525-92-6P
 RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 [(Hetero)arylsulfonylamino]-[1-substituted-piperidin-4-yl]-acetic acids as metalloprotease inhibitors
 RN 362525-92-6 HCAPIJUS
 CN 4-Piperidinecarboxamide, N-hydroxy-α-[[[4'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]-1-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 6 HCAPIJUS COPYRIGHT 2005 ACS on STN
 2001:474054 Document No. 135:210918 Potent and Selective Carboxylic Acid-Based Inhibitors of Matrix Metalloproteinases. Pikul, Stanislaw; Ohler, Norman E.; Ciszewski, Greg; Lauferweiler, Michael C.; Almstead, Neil G.; De, Biswanath; Natchus, Michael G.; Haieh, Lily C.; Janusz, Michael J.; Peng, Sean X.; Branch, Todd M.; King, Selene L.; Taiwo, Yetunde O.; Mieling, Glen E. (Health Care Research Center, Procter and Gamble Pharmaceuticals, Mason, OH, 45040, USA). Journal of Medicinal Chemistry, 44(16), 2499-2502 (English) 2001. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.
 AB A novel series of carboxylic acids containing a substituted piperidine were synthesized and tested for inhibition of selected matrix metalloproteinases. Multiple analogs prepared based on this novel design were found to inhibit the target MMPs (MMP-2, -3, -8, -9, and -13) with unprecedented, low nanomolar potency while, at the same time, sparing MMP-1 and MMP-7. Solubility and plasma protein binding of several members of this new series of carboxylic acids were also investigated.
 IT 357413-54-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of carboxylic acid-based inhibitors of matrix metalloproteinases)
 RN 357413-54-8 HCAPIJUS
 CN 1-Piperidinecarboxylic acid, 4-[2-(hydroxyamino)-1-[[[4'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]-2-oxoethyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



=> fil caol;s l3
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
32.09	200.49

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.38	-4.38

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 13:33:10 ON 16 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L5 0 L3

=> del his y

=> fil reg
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.43	200.92

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-4.38

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 13:33:42 ON 16 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2005 HIGHEST RN 845699-17-4
DICTIONARY FILE UPDATES: 15 MAR 2005 HIGHEST RN 845699-17-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>